MoonLake Immunotherapeutics (MLTX) shares fell 87% pre-bell Monday after Bloomberg reported that late-stage trial data for the company's experimental skin disease drug, sonelokimab, failed to demonstrate superiority over a rival treatment from UCB.
Maris-Tech (MTEK) stock was down 43% after the company reported late Friday weaker financial results for the six months ended June 30 versus a year earlier.
Precipio (PRPO) shares were 15% lower, adding to Friday's loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.